Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study

Bone Marrow Transplantation volume 35, pages 1025–1026 (2005)Cite this article

Chronic graft versus host disease (cGVHD) incidence and severity are generally found to be greater after peripheral blood stem cell transplantation (SCT) than after bone marrow transplantation, even if few exceptions are reported,1 and some studies demonstrate a worse outcome due to increased mortality from GVHD, particularly the extensive type.2 In vivo T-cell depletion with antithymocyte globulin (ATG) is an effective strategy to decrease the incidence of GVHD. The dose and type of polyclonal antibodies are only partially defined because of wide differences in antibody specificities.3 GVHD prophylaxis with ATGs may include unwanted side effects such as high risk of infection and relapse.4, 5 The main utilization of ATG has been for the prophylaxis of GVHD in unrelated bone marrow transplants, with clear benefit.4, 6 We previously showed that low-dose (15 mg/kg, total dose) ATG-Fresenius (F, Bad Homburg, Germany) was able to decrease the incidence of GVHD after unrelated myeloablative transplants in CML without an increase of relapse.7 The high anti-CTLA-4 activity present in ATG-F preparation, downregulating the CD28-mediated stimulation of T cells, could partly explain the protective effect on GVHD occurrence.3

With regard to family donors, instead, ATG-F has been used with bone marrow,6 while in peripheral blood SCT, it has been almost exclusively associated with reduced-intensity conditioning (RIC).8

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Elmaagacli AH, Basoglu S, Peceny R et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130–1135.

    CAS  PubMed  Google Scholar 

  2. Mohty M, Kuentz M, Michallet M et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long term results of a randomized study. Blood 2002; 100: 3128–3134.

    Article  CAS  PubMed  Google Scholar 

  3. Pistillo MP, Tazzari PL, Bonifazi F et al. Detection of a novel specificity (CTLA-4) in ATG/TMG globulin and sera from ATG-treated leukemic patients. Transplantation 2002; 73: 1295–1302.

    Article  CAS  PubMed  Google Scholar 

  4. Bacigalupo A, Lamparelli T, Guidi S et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947.

    Article  CAS  PubMed  Google Scholar 

  5. Remberger M, Svahn BM, Hentschke P et al. Effect on cytokine-release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haemopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823–830.

    Article  CAS  PubMed  Google Scholar 

  6. Kroger N, Zabelina T, Kruger W et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002; 29: 683–689.

    Article  CAS  PubMed  Google Scholar 

  7. Bonifazi F, Bandini G, Rondelli D et al. Reduced incidence of GVHD with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. Bone Marrow Transplant 2003; 32: 237–242.

    Article  CAS  PubMed  Google Scholar 

  8. Schetelig J, Borhauser M, Kiehl M et al. Reduced intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation – a retrospective analysis. Bone Marrow Transplant 2004; 33: 483–490.

    Article  CAS  PubMed  Google Scholar 

  9. Gratwohl A, Baldomero H, Urbano-Ispizua A . Transplantation in chronic myeloid leukemia. Lancet 2002; 359: 712–713.

    Article  CAS  PubMed  Google Scholar 

  10. Schleuning M, Gunther W, Tischer J et al. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003; 32: 243–250.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Hematology ‘L. and A. Seràgnoli’, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy

    F Bonifazi, G Bandini, M Stanzani, F Palandri, B Giannini, M Arpinati, G Rosti & M Baccarani

Authors
  1. F Bonifazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Bandini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Stanzani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Palandri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Giannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Arpinati
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Rosti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Baccarani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonifazi, F., Bandini, G., Stanzani, M. et al. In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. Bone Marrow Transplant 35, 1025–1026 (2005). https://doi.org/10.1038/sj.bmt.1704940

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704940

This article is cited by

Search

Advanced search

Quick links